Cellular mechanisms of beta-amyloid production and secretion.

The major constituent of senile plaques in Alzheimer's disease is a 42-aa peptide, referred to as beta-amyloid (Abeta). Abeta is generated from a family of differentially spliced, type-1 transmembrane domain (TM)-containing proteins, called APP, by endoproteolytic processing. The major, relatively ubiquitous pathway of APP metabolism in cell culture involves cleavage by alpha-secretase, which cleaves within the Abeta sequence, thus precluding Abeta formation and deposition. An alternate secretory pathway, enriched in neurons and brain, leads to cleavage of APP at the N terminus of the Abeta peptide by beta-secretase, thus generating a cell-associated beta-C-terminal fragment (beta-CTF). A pathogenic mutation at codons 670/671 in APP (APP "Swedish") leads to enhanced cleavage at the beta-secretase scissile bond and increased Abeta formation. An inhibitor of vacuolar ATPases, bafilomycin, selectively inhibits the action of beta-secretase in cell culture, suggesting a requirement for an acidic intracellular compartment for effective beta-secretase cleavage of APP. beta-CTF is cleaved in the TM domain by gamma-secretase(s), generating both Abeta 1-40 (90%) and Abeta 1-42 (10%). Pathogenic mutations in APP at codon 717 (APP "London") lead to an increased proportion of Abeta 1-42 being produced and secreted. Missense mutations in PS-1, localized to chromosome 14, are pathogenic in the majority of familial Alzheimer's pedigrees. These mutations also lead to increased production of Abeta 1-42 over Abeta 1-40. Knockout of PS-1 in transgenic animals leads to significant inhibition of production of both Abeta 1-40 and Abeta 1-42 in primary cultures, indicating that PS-1 expression is important for gamma-secretase cleavages. Peptide aldehyde inhibitors that block Abeta production by inhibiting gamma-secretase cleavage of beta-CTF have been discovered.

[1]  K. Grzeschik,et al.  The precursor of Alzheimer's disease amyloid A4 protein resembles a cell-surface receptor , 1987, Nature.

[2]  D. Selkoe,et al.  Mutation of the β-amyloid precursor protein in familial Alzheimer's disease increases β-protein production , 1992, Nature.

[3]  P. Malherbe,et al.  Expression and characterization of human beta-secretase candidates metalloendopeptidase MP78 and cathepsin D in beta APP-overexpressing cells. , 1997, Brain research. Molecular brain research.

[4]  D. Selkoe.  The molecular pathology of Alzheimer's disease , 1991, Neuron.

[5]  L. Thal,et al.  Secretion of β-amyloid precursor protein cleaved at the amino terminus of the β-amyloid peptide , 1993, Nature.

[6]  R. Neve,et al.  The Alzheimer amyloid precursor protein. Identification of a stable intermediate in the biosynthetic/degradative pathway. , 1990, The Journal of biological chemistry.

[7]  J. S. Jacobsen,et al.  Evaluation of Cathepsins D and G and EC 3.4.24.15 as Candidate β‐Secretase Proteases Using Peptide and Amyloid Precursor Protein Substrates , 1996, Journal of neurochemistry.

[8]  I. Lieberburg,et al.  Evidence for a nonsecretory, acidic degradation pathway for amyloid precursor protein in 293 cells. Identification of a novel, 22-kDa, beta-peptide-containing intermediate. , 1992, The Journal of biological chemistry.

[9]  K. Beyreuther,et al.  Amyloid precursor protein secretion and βA4 amyloid generation are not mutually exclusive , 1994, FEBS letters.

[10]  G. Schellenberg,et al.  Candidate gene for the chromosome 1 familial Alzheimer's disease locus , 1995, Science.

[11]  Joseph D. Buxbaum,et al.  Evidence That Tumor Necrosis Factor α Converting Enzyme Is Involved in Regulated α-Secretase Cleavage of the Alzheimer Amyloid Protein Precursor* , 1998, The Journal of Biological Chemistry.

[12]  I. Lieberburg,et al.  Cells with a familial Alzheimer's disease mutation produce authentic beta-peptide. , 1993, Neuroreport.

[13]  Andreas Weidemann,et al.  Identification, biogenesis, and localization of precursors of Alzheimer's disease A4 amyloid protein , 1989, Cell.

[14]  S. Sisodia.  Beta-amyloid precursor protein cleavage by a membrane-bound protease. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[15]  A. Goate,et al.  Monogenetic determinants of Alzheimer's disease: APP mutations , 1998, Cellular and Molecular Life Sciences CMLS.

[16]  D. Selkoe,et al.  Amyloid β-peptide is produced by cultured cells during normal metabolism , 1992, Nature.

[17]  B. Winblad,et al.  A pathogenic mutation for probable Alzheimer's disease in the APP gene at the N–terminus of β–amyloid , 1992, Nature Genetics.

[18]  D. Pollen,et al.  Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease , 1995, Nature.

[19]  J. Growdon,et al.  Release of Alzheimer amyloid precursor derivatives stimulated by activation of muscarinic acetylcholine receptors. , 1992, Science.

[20]  N. Hooper,et al.  Membrane protein secretases. , 1997, The Biochemical journal.

[21]  J. Wiseman,et al.  Inhibition of the proteolysis of rat erythrocyte membrane proteins by a synthetic inhibitor of calpain. , 1988, Biochemical and biophysical research communications.

[22]  P. Greengard,et al.  Protein phosphorylation inhibits production of Alzheimer amyloid beta/A4 peptide. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[23]  M. Blaber,et al.  The protease inhibitory properties of the Alzheimer's beta-amyloid precursor protein. , 1990, The Journal of biological chemistry.

[24]  D. Selkoe,et al.  Generation of amyloid β protein from its precursor is sequence specific , 1995, Neuron.

[25]  Weiming Xia,et al.  Mutant presenilins of Alzheimer's disease increase production of 42-residue amyloid β-protein in both transfected cells and transgenic mice , 1997, Nature Medicine.

[26]  D. Selkoe,et al.  Two transmembrane aspartates in presenilin-1 required for presenilin endoproteolysis and γ-secretase activity , 1999, Nature.

[27]  D. Selkoe,et al.  Isolation and quantification of soluble Alzheimer's β-peptide from biological fluids , 1992, Nature.

[28]  B. Greenberg,et al.  A new A4 amyloid mRNA contains a domain homologous to serine proteinase inhibitors , 1988, Nature.

[29]  S. Younkin,et al.  An increased percentage of long amyloid beta protein secreted by familial amyloid beta protein precursor (beta APP717) mutants. , 1994, Science.

[30]  Hugo Vanderstichele,et al.  Deficiency of presenilin-1 inhibits the normal cleavage of amyloid precursor protein , 1998, Nature.

[31]  L. McConlogue,et al.  Cell-type and Amyloid Precursor Protein-type Specific Inhibition of Aβ Release by Bafilomycin A1, a Selective Inhibitor of Vacuolar ATPases (*) , 1995, The Journal of Biological Chemistry.

[32]  Iva Greenwald,et al.  Facilitation of lin-12-mediated signalling by sel-12, a Caenorhabditis elegans S182 Alzheimer's disease gene , 1995, Nature.

[33]  Kenneth S. Kosik,et al.  The E280A presenilin 1 Alzheimer mutation produces increased Aβ42 deposition and severe cerebellar pathology , 1996, Nature Medicine.

[34]  T. Oltersdorf,et al.  Cleavage of amyloid beta peptide during constitutive processing of its precursor. , 1990, Science.

[35]  Neurodegenerative Alzheimer-like pathology in PDAPP 717V-->F transgenic mice. , 1998, Progress in brain research.

[36]  Nicole Nelson,et al.  A metalloproteinase disintegrin that releases tumour-necrosis factor-α from cells , 1997, Nature.

[37]  C. Masters,et al.  Distinct sites of intracellular production for Alzheimer's disease Aβ40/42 amyloid peptides , 1997, Nature Medicine.

[38]  Y. Moriyama,et al.  Bafilomycin A1, a specific inhibitor of vacuolar-type H(+)-ATPase, inhibits acidification and protein degradation in lysosomes of cultured cells. , 1991, The Journal of biological chemistry.

[39]  P. Greengard,et al.  Processing of Alzheimer beta/A4 amyloid precursor protein: modulation by agents that regulate protein phosphorylation. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[40]  K. Johnson-wood,et al.  The secreted form of the Alzheimer's amyloid precursor protein with the Kunitz domain is protease nexin-II , 1989, Nature.

[41]  J. Massagué,et al.  Diverse Cell Surface Protein Ectodomains Are Shed by a System Sensitive to Metalloprotease Inhibitors (*) , 1996, The Journal of Biological Chemistry.

[42]  J. Higaki,et al.  Inhibition of β-amyloid formation identifies proteolytic precursors and subcellular site of catabolism , 1995, Neuron.

[43]  L. Mucke,et al.  Alzheimer-type neuropathology in transgenic mice overexpressing V717F β-amyloid precursor protein , 1995, Nature.

[44]  K. Beyreuther,et al.  Mechanism of the cleavage specificity of Alzheimer's disease gamma-secretase identified by phenylalanine-scanning mutagenesis of the transmembrane domain of the amyloid precursor protein. , 1999, Proceedings of the National Academy of Sciences of the United States of America.